COLL vs CRON

Collegium Pharmaceutical, Inc. vs Cronos Group Inc. Common Share — Valuation Comparison 2026

COLL

Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc.
Quality
9.2
out of 10
Value Trap
23
SAFE
Price
$33.37
Last close
Models
12/13
Active
VS

CRON

Drug Manufacturers - Specialty & Generic
Cronos Group Inc. Common Share
Quality
5.2
out of 10
Value Trap
18
SAFE
Price
$2.84
Last close
Models
12/13
Active

Model-by-Model Comparison

ModelType COLL Fair ValueCOLL Upside CRON Fair ValueCRON Upside
Bayesian DCF Intrinsic $138.55 +315.2% $2.91 +2.3%
Earnings Power Value Intrinsic $30.34 -9.1% $2.00 -29.6%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for COLL vs CRON — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

COLL vs CRON — Which Stock Is More Undervalued?

COLL scores higher with a 9.2/10 quality rating vs CRON's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Collegium Pharmaceutical, Inc. (COLL) and Cronos Group Inc. Common Share (CRON) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

COLL currently trades at $33.37 with a QOC of 9.2/10, while CRON trades at $2.84 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).

COLL
View Full Collegium Pharmaceutical, Inc. Analysis →
CRON
View Full Cronos Group Inc. Common Share Analysis →